New hope for metastatic breast cancer patients who've run out of options
NCT ID NCT06100874
Summary
This study is testing whether combining two targeted drugs—sacituzumab govitecan and trastuzumab—can help control metastatic HER2-positive breast cancer that has progressed after standard treatments. The trial will enroll about 28 patients who have already received specific prior therapies to evaluate how well the combination works and how safe it is. Researchers will measure whether tumors shrink and how long patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
DFCI @ South Shore Hospital
South Weymouth, Massachusetts, 02190, United States
-
Dana Farber Cancer Institite
Boston, Massachusetts, 02215, United States
-
Miami Cancer Institute at Baptist Health
Miami, Florida, 33176, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.